New Roles of Carnitine Metabolism in Ammonia Cytotoxicity
- 71 Downloads
High levels of ammonia in blood and brain due to metabolic disorders are associated with neurological abnormalities. Although the mechanism of ammonia toxicity at the CNS level is still unknown, alterations in brain energy metabolism, in neurotransmitter function and direct effects on nervous impulse have been proposed. In most hyperammonemic conditions morphological changes in the liver and brain have been demonstrated, especially in mitochondria, endoplasmic reticulum and lysosomes, together with an accumulation of intracellular lipids. The treatment of hyperammonemias is uncertain and mostly directed to reduce the level of circulating ammonia; there is no current therapy aimed to counteract the molecular effects of ammonia. Administration of carnitine prevents acute ammonia toxicity and enhances the efficacy of ammonia elimination as urea and glutamine. In addition the cytotoxic effects of ammonia, possibly arising from lipid peroxidation, are ameliorated by carnitine. These data indicate the feasibility of utilization of carnitine in the therapy of human hyperammonemic syndromes, both for reducing the levels of ammonia and preventing its toxic effects.
KeywordsHepatic Encephalopathy Sodium Benzoate Ammonia Elimination Carnitine Deficiency Ammonia Toxicity
Unable to display preview. Download preview PDF.
- 1.Duffy TE and Plum F: Hepatic encephalopathy. In (Arias I, Popper H, Schachter D and Shafritz D, eds) The Liver: Biology and Pathobiology. New York, Raven Press, pp 693–795, 1982.Google Scholar
- 2.Walser M: Urea cycle disorders and other hereditary hyperammonemic syndromes. In (Stanbury JB, Wyngaarden JB and Fredrickson DS, eds) The Metabolic Basis of Inherited Diseases. New York, McGraw-Hill, pp 402–438. 1982.Google Scholar
- 3.Rosenberg, LE: Disorders of propionate, methylmalonate and cobalamin metabolism. In (Stanbury JB, Wyngaarden JB and Fredrikson DS, eds) The Metabolic Basis of Inherited Diseases. New York, McGraw-Hill, pp 411–429, 1978.Google Scholar
- 5.Glasgow AM: The role of hyperammonemia in Reye’s syndrome. J. Natl. Reye’s Syndrome Found. 4: 24–31, 1984.Google Scholar
- 11.Conn HO and Lieberthal MN: The Hepatic Coma Syndromes and Lactulose. Baltimore, Williams and Wilkins, 1979.Google Scholar
- 14.Popper H: Introduction. In (Keppler D, Popper H, Bianchi L and Reutter W, eds) Mechanisms of Hepatocyte Injury and Death. Lancaster, MTP Press, pp 11–30, 1984.Google Scholar
- 19.O’Connor JE, Guerri C and Grisolía S: Protective effect of tert-butanol on hyperammonemia. New England J. Med. 347: 254, 1982.Google Scholar
- 31.O’Connor JE, Gollerkeri A and Kimler BF: Flow cytometric analysis of cytotoxic effects of ammonia on murine neuroblastoma. Bas. Appl. histochem. 32: 379, 1988.Google Scholar
- 32.O’Connor JE, Kimler BF, Gollerkeri A, Costell M and Grisolía S: Flow cytometric analysis of ammonia toxicity in cultured murine neuroblastoma cells. Cytometry (in press), 1990.Google Scholar
- 33.Petit PX, Costell M, O’Connor JE and Matthes M: Flow cytometry analysis of Rhl23 membrane potential related fluorescence in isolated mitochondria from hyperammonemic mice. Biol. Cell 67: 29a, 1989.Google Scholar
- 36.O’Connor JE, Costell M, Miguez MP and Grisolía S: Altera-ciones del metabolismo hepético de los acidos grasos en 1a hiperamonemia crónica experimental. Pharmacia Mediterranea 16: 846–857,1986.Google Scholar